Abstract

Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer. Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression. PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors. In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.

Keywords

PI3K/AKT/mTOR pathwayBiologyClinical trialCancerProtein kinase BRegulatorCancer researchSignal transductionBioinformaticsCell biologyGenetics

MeSH Terms

AnimalsAntineoplastic AgentsClinical Trials as TopicDrug ResistanceNeoplasmGene Expression RegulationNeoplasticHumansMolecular Targeted TherapyNeoplasmsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine Kinases

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
review
Volume
18
Issue
1
Pages
26-26
Citations
1491
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1491
OpenAlex
36
Influential

Cite This

Jing Yang, Ji Nie, Xuelei Ma et al. (2019). Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer , 18 (1) , 26-26. https://doi.org/10.1186/s12943-019-0954-x

Identifiers

DOI
10.1186/s12943-019-0954-x
PMID
30782187
PMCID
PMC6379961

Data Quality

Data completeness: 90%